← Back to Screener
NRX Pharmaceuticals, Inc. Common Stock (NRXP)
Price$4.14
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)61.05%
Price vs S&P 500 (4W)34.43%
VGM Score73.94
Market Capitalization$149.99M
All Metrics
Book Value / Share (Quarterly)$1.12
P/TBV (Annual)3.61x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.45
Price vs S&P 500 (YTD)44.61%
EPS (TTM)$-1.28
10-Day Avg Trading Volume2.25M
EPS Excl Extra (TTM)$-1.28
EPS (Annual)$-1.34
ROI (Annual)-221.67%
Gross Margin (Annual)58.78%
Cash / Share (Quarterly)$0.20
ROA (Last FY)-220.92%
EBITD / Share (TTM)$-0.85
ROE (5Y Avg)-206.78%
Cash Flow / Share (Annual)$-0.44
P/B Ratio20.24x
P/B Ratio (Quarterly)10.13x
Net Income / Employee (Annual)$-987,000
Net Interest Coverage (TTM)-40.24x
ROA (TTM)-219.64%
EPS Incl Extra (Annual)$-1.34
Current Ratio (Annual)0.31x
Quick Ratio (Quarterly)0.27x
3-Month Avg Trading Volume1.03M
52-Week Price Return40.82%
Tangible BV / Share (Quarterly)$-0.07
P/S Ratio (Annual)122.44x
Asset Turnover (Annual)0.09x
52-Week High$5.05
EPS Excl Extra (Annual)$-1.34
Tangible BV CAGR (5Y)-36.09%
26-Week Price Return68.98%
Quick Ratio (Annual)0.28x
13-Week Price Return133.90%
Total Debt / Equity (Annual)1.42x
Current Ratio (Quarterly)0.29x
Enterprise Value$143.28M
Book Value / Share Growth (5Y)-57.11%
Revenue / Employee (Annual)$42,200
Pretax Margin (Annual)-2336.49%
Cash / Share (Annual)$0.25
3-Month Return Std Dev114.43%
Net Income / Employee (TTM)$-846,200
ROE (Last FY)-536.56%
Net Interest Coverage (Annual)-0.15x
EPS Basic Excl Extra (Annual)$-1.34
Total Debt / Equity (Quarterly)1.42x
EPS Incl Extra (TTM)$-1.28
ROI (TTM)-172.32%
Revenue / Share (Annual)$0.06
Tangible BV / Share (Annual)$0.11
Forward P/E3.91x
Price vs S&P 500 (52W)16.45%
Year-to-Date Return52.77%
5-Day Price Return-10.39%
EPS Normalized (Annual)$-1.34
ROA (5Y Avg)-351.92%
Net Profit Margin (Annual)-2336.49%
Month-to-Date Return-6.33%
Cash Flow / Share (TTM)$-0.50
EBITD / Share (Annual)$-1.04
Operating Margin (Annual)-1830.61%
LT Debt / Equity (Annual)0.38x
ROI (5Y Avg)-135.89%
LT Debt / Equity (Quarterly)0.38x
EPS Basic Excl Extra (TTM)$-1.28
P/B Ratio (Annual)10.13x
Book Value / Share (Annual)$1.12
Price vs S&P 500 (13W)125.64%
Beta2.14x
ROE (TTM)-195.76%
52-Week Low$1.62
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.04est. 0.29
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRXPNRX Pharmaceuticals, Inc. Common Stock | — | — | B | $4.14 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
NRX Pharmaceuticals is a clinical-stage pharmaceutical company developing small-molecule therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company has commercialized ZYESAMI (Aviptadil) for COVID-related respiratory failure and is advancing NRX-100/101, a sequential treatment regimen for bipolar depression in patients with acute suicidal ideation. Its pipeline targets unmet needs in critical care and psychiatry.